The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management

This educational program consists of four presentations on LDL-c-lowering therapies

The evolving need and challenges to reach LDL-c targets in high-risk patients - Kausik Ray, MD - London, UK

• According to the latest registries, the majority of high- and very high-risk patients do not achieve the 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.

Oral cholesterol-lowering therapies: The basis of prevention - Lale Tokgözoğlu, MD - Ankara, Turkey

• "Oral cholesterol-lowering therapies are the basis of cardiovascular disease prevention", says Lale Tokgözoğlu. In this video, she talks about oral therapies.

PCSK9i: Benefits across the spectrum of cardiovascular disease - Fabrice Martens, MD, PhD - Amsterdam, The Netherlands

• Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.

Novel oral pathways in LDL-c lowering therapy: The new promise of CETPi - Erin Michos, MD - Baltimore, MD, USA

• Erin Michos talks about CETPi as a novel opportunity for oral LDL-c lowering therapy. She explains the mechanism of action of CETPi and discusses past and ongoing studies with CETPi.